

SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

JAN 07 2008

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)

(37 C.F.R. § 1.98(b))

Attorney Docket No. 50026/057001
 Serial No. 10/562,408
 Applicant You et al.
 371(c) Date Dec. 7, 2006
 Group 1636
 IDS Filed January 2, 2008

U.S. PATENT DOCUMENTS

Examiner's Initials	Document Number	Issue or Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	10/111,356		Yonemitsu et al.			Jul. 30, 2002
	2002/0002143	Jan. 3, 2002	Kano et al.			
	2002/0098576	Jul. 25, 2002	Nagai et al.			
	2002/0100066	Jul. 25, 2002	Nagai et al.			
	2002/0169306	Nov. 14, 2002	Kitazato et al.			
	2003/0022376	Jan. 30, 2003	Kitazato et al.			
	2003/0166252	Sep. 4, 2003	Kitazato et al.			
	2003/0170210	Sep. 11, 2003	Masaki et al.			
	2003/0170266	Sep. 11, 2003	Kitazato et al.			
	2003/0170897	Sep. 11, 2003	Imai et al.			
	2003/0203489	Oct. 30, 2003	Yonemitsu et al.			
	2004/0005296	Jan. 8, 2004	Yonemitsu et al.			
	2004/0053877	Mar. 18, 2004	Fukumura et al.			
	2004/0101965	May 27, 2004	Griesenbach et al.			
	2004/0121308	Jun. 24, 2004	Nagai et al.			
	2005/0130123	Jun. 16, 2005	Inoue et al.			
	2005/0191617	Sep. 1, 2005	Inoue et al.			
	2005/0221292	Oct. 6, 2005	Kinoh et al.			

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AW/ (03/22/2009)

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No.	50026/057001
				Serial No.	10/562,408
				Applicant	You et al.
				371(c) Date	Dec. 7, 2006
				Group	1636
				IDS Filed	January 2, 2008
(37 C.F.R. § 1.98(b))					

	2005/0250718	Nov. 10, 2005	Sakakibara et al.			
	2005/0266566	Dec. 1, 2005	Nagai et al.			
	2006/0104950	May 18, 2006	Okano et al.			
	2006/0216824	Sep. 28, 2006	Tokusumi et al.			
	2007/0269414	Nov. 22, 2007	Okano et al.			
	5,670,488	Sep. 23, 1997	Gregory et al.			
	5,824,655	Oct. 20, 1998	Border			
	5,958,893	Sep. 28, 1999	Welsh et al.			
	5,962,274	Oct. 5, 1999	Parks			
	6,040,174	Mar. 21, 2000	Imler et al.			
	6,645,760	Nov. 11, 2003	Nagai et al.			
	6,723,532	Apr. 20, 2004	Nagai et al.			
	6,740,750	May 25, 2004	Taira et al.			
	6,746,860	Jun. 8, 2004	Tokusumi et al.			
	6,828,138	Dec. 7, 2004	Nagai et al.			

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	AU 7335196 A	May 22, 1997	Australia			
	AU 200046146 A	Dec. 5, 2000	Australia			
	AU 200110551 A	May 14, 2001	Australia			
	CA 2236113 A1	May 9, 1997	Canada			

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AW/ (03/22/2009)

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No.	50026/057001
				Serial No.	10/562,408
				Applicant	You et al.
				371(c) Date	Dec. 7, 2006
				Group	1636
(37 C.F.R. § 1.98(b))				IDS Filed	January 2, 2008

	CN 1207123 A, B	Feb. 3, 1999	China		
	CN 1355851 A	Jun. 26, 2002	China		
	CN 1357044 A	Jul. 3, 2002	China		
	EP 0 863 202 A1	Sep. 9, 1998	EPO		
	EP 0 864 645 A1	Sep. 16, 1998	EPO		
	EP 1 106 692 A1	Jun. 13, 2001	EPO		
	EP 1 179 594 A1	Feb. 13, 2002	EPO		
	EP 1 186 667 A1	Mar. 13, 2002	EPO		
	EP 1 325 960 A2	Jul. 9, 2003	EPO		
	HK 1018287 A1	Nov. 21, 2003	Hong Kong		
	JP 7-509616 A1	Oct. 26, 1995	Japan		Claims only
	JP 10-506542 A1	Jun. 30, 1998	Japan		Yes
	JP 2003-513633A	Apr. 15, 2003	Japan		No
	KR 2002014786 A	Feb. 25, 2002	Korea		
	KR 2002037930 A		Korea		
	WO 97/16171 A1	May 9, 1997	WIPO		Abstract only
	WO 97/16538 A1	May 9, 1997	WIPO		Yes
	WO 97/16539 A1	May 9, 1997	WIPO		Yes
	WO 00/09700 A1	Feb. 24, 2000	WIPO		Abstract only
	WO 00/27430 A3	May 18, 2000	WIPO		Abstract only
	WO 00/70055 A1	Nov. 23, 2000	WIPO		Yes
	WO 00/70070 A1	Nov. 23, 2000	WIPO		Yes

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AW/ (03/22/2009)

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No.	50026/057001
				Serial No.	10/562,408
				Applicant	You et al.
				371(c) Date	Dec. 7, 2006
				Group	1636
				IDS Filed	January 2, 2008
(37 C.F.R. § 1.98(b))					

	WO 01/20989 A1	Mar. 29, 2001	WIPO		
	WO 01/32898 A2, A3	May 10, 2001	WIPO		
	WO 03/025570 A1	Mar. 27, 2003	WIPO		Yes
	WO 03/092738 A1	Nov. 13, 2003	WIPO		Yes
	WO 03/093476 A1	Nov. 13, 2003	WIPO		Yes
	WO 03/102183 A1	Dec. 11, 2003	WIPO		Yes
	WO 04/038029 A1	May 6, 2004	WIPO		Yes

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

	Ali et al., "Assembly of Sendai Virus: M Protein Interacts with F and HN Proteins and with the Cytoplasmic Tail and Transmembrane Domain of F Protein," <i>Virology</i> 276(2):289-303 (2000).
	Altenschmidt et al., "Specific Cytotoxic T Lymphocytes in Gene Therapy," <i>J. Mol. Med.</i> 75(4):259-266 (1997).
	Arai et al., "A New System for Stringent, High-Titer Vesicular Stomatitis Virus G Protein-Pseudotyped Retrovirus Vector Induction by Introduction of Cre Recombinase into Stable Prepackaging Cell Lines," <i>J. Virol.</i> 72(2):1115-1121 (1998).
	Auten et al., "Effect of Scaffold Attachment Region on Transgene Expression in Retrovirus Vector-Transduced Primary T Cells and Macrophages," <i>Hum. Gene Ther.</i> 10(8):1389-1399 (1999).
	Ayuk et al., "Establishment of an Optimised Gene Transfer Protocol for Human Primary T Lymphocytes According to Clinical Requirements," <i>Gene Ther.</i> 6(10):1788-1792 (1999).
	Bagai et al., "Hemagglutinin-Neuraminidase Enhances F Protein-Mediated Membrane Fusion of Reconstituted Sendai Virus Envelopes with Cells," <i>J. Virol.</i> 67(6):3312-3318 (1993).
	Barclay et al., "Influenza B Viruses with Site-Specific Mutations Introduced into the HA Gene," <i>J. Virol.</i> 69(2):1275-1279 (1995).
	Bergemann et al., "Excision of Specific DNA-Sequences from Integrated Retroviral Vectors via Site-Specific Recombination," <i>Nucleic Acids Res.</i> 23(21):4451-4456 (1995).
	Bitzer et al., "Sendai Virus Efficiently Infects Cells via the Asialoglycoprotein Receptor and Requires the Presence of Cleaved F ₀ Precursor Proteins for This Alternative Route of Cell Entry," <i>J. Virol.</i> 71(7):5481-5486 (1997).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U. S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No.	50026/057001
		INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/562,408
				Applicant	You et al.
				371(c) Date	Dec. 7, 2006
				Group	1636
				IDS Filed	January 2, 2008
(37 C.F.R. § 1.98(b))					

	Blaese et al., "T Lymphocyte-Directed Gene Therapy for ADA" SCID: Initial Trial Results After 4 Years," <i>Science</i> 270(5235):475-480 (1995).
	Brenner, "Gene Transfer to Hematopoietic Cells," <i>New Engl. J. Med.</i> 335(5):337-339 (1996).
	Brösamle et al., "Regeneration of Lesioned Corticospinal Tract Fibers in the Adult Rat Induced by a Recombinant, Humanized IN-1 Antibody Fragment," <i>J. Neurosci.</i> 20(21):8061-8068 (2000).
	Brown et al., "Sorting of GPI-Anchored Proteins to Glycolipid-Enriched Membrane Subdomains during Transport to the Apical Cell Surface," <i>Cell</i> 68(3):533-544 (1992).
	Buchsacher et al., "Development of Lentiviral Vectors for Gene Therapy for Human Diseases," <i>Blood</i> 95(8):2499-2504 (2000).
	Bunnell et al., "Efficient In Vivo Marking of Primary CD4 ⁺ T Lymphocytes in Nonhuman Primates Using a Gibbon Ape Leukemia Virus-Derived Retroviral Vector," <i>Blood</i> 89(6):1987-1995 (1997).
	Cannon et al., "Pseudomonas aeruginosa-Induced Apoptosis is Defective in Respiratory Epithelial Cells Expressing Mutant Cystic Fibrosis Transmembrane Conductance Regulator," <i>Am. J. Respir. Cell Mol. Biol.</i> 29(2):188-197 (2003).
	Caravokyri et al., "Defective Synthesis of Envelope Proteins by Temperature-Sensitive Mutants Representing Complementation Groups B and D of Respiratory Syncytial Virus," <i>J. Gen. Viro.</i> 72(10):2501-2508 (1991).
	Carroll et al., "Synthesis and Secretion of a Functional Antibody in a Vaccinia Virus Expression System," <i>Mol. Immunol.</i> 29(7-8):821-827 (1992).
	Cathomen et al., "A Matri-Less Measles Virus Is Infectious and Elicits Extensive Cell Fusion: Consequences for Propagation in the Brain," <i>EMBO J.</i> 17(14):3899-3908 (1998).
	Cathomen et al., "Measles Viruses with Altered Envelope Protein Cytoplasmic Tails Gain Cell Fusion Competence," <i>J. Virol.</i> 72(2):1224-1234 (1998).
	Chen et al., "A Unique Substrate Recognition Profile for Matrix Metalloproteinase-2," <i>J. Biol. Chem.</i> 277(6):4485-4491 (2002).
	Conzelmann, "Nonsegmented Negative-Strand RNA Viruses: Genetics and Manipulation of Viral Genomes," <i>Annu. Rev. Genet.</i> 32:123-162 (1998).
	Costello et al., "Gene Transfer into Stimulated and Unstimulated T Lymphocytes by HIV-1-Derived Lentiviral Vectors," <i>Gene Ther.</i> 7(7):596-604 (2000).
	Dardalhon et al., "Lentivirus-Mediated Gene Transfer in Primary T Cells Is Enhanced by a Central DNA Flap," <i>Gene Ther.</i> 8(3):190-198 (2001).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No. Serial No. Applicant 371(c) Date Group IDS Filed	50026/057001 10/562,408 You et al. Dec. 7, 2006 1636 January 2, 2008
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
(37 C.F.R. § 1.98(b))			

	Delaney et al., "Cystic Fibrosis Mice Carrying the Missense Mutation G551D Replicate Human Genotype-Phenotype Correlations," <i>The EMBO Journal</i> 15(5):955-963 (1996).
	Deonarain, "Ligand-Targeted Receptor-Mediated Vectors for Gene Delivery," <i>Exp. Opin. Ther. Pat.</i> 8(1):53-69 (1998).
	Di Nicola et al., "Recombinant Adenoviral Vector-LipofectAMINE Complex for Gene Transduction into Human T Lymphocytes," <i>Hum. Gene Ther.</i> 10(11):1875-1884 (1999).
	Douglas et al., "Targeted Gene Delivery by Tropism-Modified Adenoviral Vectors," <i>Nat. Biotechnol.</i> 14(11):1574-1578 (1996).
	Dzau et al., "Fusogenic Viral Liposome for Gene Therapy in Cardiovascular Diseases," <i>Proc. Natl. Acad. Sci. USA</i> 93(21):11421-11425 (1996).
	Eck et al., <i>Goodman and Gilman's The Pharmacological Basis of Therapeutics</i> , 9 th ed., McGraw-Hill: New York, pp. 77-101 (1996).
	Friedman, "Expression of Human Adenosine Deaminase Using a Transmissible Murine Retrovirus Vector System," <i>Proc. Natl. Acad. Sci. USA</i> 82(3):703-707 (1985).
	Funato et al., "Anti-K-ras Ribozyme Induces Growth Inhibition and Increased Chemosensitivity in Human Colon Cancer Cells," <i>Cancer Gene Ther.</i> 7(3):495-500 (2000).
	Garoff et al., "Virus Maturation by Budding," <i>Microbiol. Mol. Biol. Rev.</i> 62(4):1171-1190 (1998).
	Ghivizzani et al., "Direct Retrovirus-Mediated Gene Transfer to the Synovium of the Rabbit Knee: Implications for Arthritis Gene Therapy," <i>Gene Ther.</i> 4(9):977-982 (1997).
	Gitman et al., "Use of Virus-Attached Antibodies or Insulin Molecules to Mediate Fusion between Sendai Virus Envelopes and Neuraminidase-Treated Cells," <i>Biochemistry</i> 24(11):2762-2768 (1985).
	Gladow et al., "MLV-10A1 Retrovirus Pseudotype Efficiently Transduces Primary Human CD4 ⁺ T Lymphocytes," <i>J. Gene Med.</i> 2(6):409-415 (2000).
	Gómez-Puertas et al., "Influenza Virus Matrix Protein Is the Major Driving Force in Virus Budding," <i>J. Virol.</i> 74(24):11538-11547 (2000).
	Grecki, "Prospects and Problems of Gene Therapy: An Update," <i>Expert Opin. Emerg. Drugs</i> 6(2):187-198 (2001).
	Gould, "Comparison of the Deduced Matrix and Fusion Protein Sequences of Equine Morbillivirus with Cognate Genes of the Paramyxoviridae," <i>Virus Res.</i> 43(1):17-31 (1996).
	Griesenbach et al., "Update on Gene Therapy for Cystic Fibrosis," <i>Curr. Opin. Mol. Ther.</i> 5(5):489-494 (2003).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AW/ (03/22/2009)

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Attorney Docket No.	50026/057001
		Serial No.	10/562,408
		Applicant	You et al.
		371(c) Date	Dec. 7, 2006
		Group	1636
(37 C.F.R. § 1.98(b))		IDS Filed	January 2, 2008

	Harcourt et al., "Molecular Characterization of Nipah Virus, a Newly Emergent Paramyxovirus," <i>Virology</i> 271(2):334-349 (2000).
	Hasan et al., "Creation of an Infectious Recombinant Sendai Virus Expressing the Firefly Luciferase Gene from the 3' Proximal First Locus," <i>J. Gen. Virol.</i> 78(11):2813-2820 (1997).
	Hatanaka (ed.), <i>Uirusugaku, Asakura Shoten</i> , pp. 247-248 (1997) (with English language translation).
	Hege et al., "T-Cell Gene Therapy," <i>Curr. Opin. Biotechnol.</i> 7(6):629-634 (1996).
	Heggeness et al., "In Vitro Assembly of the Nonglycosylated Membrane Protein (M) of Sendai Virus," <i>Proc. Natl. Acad. Sci. USA</i> 79(20):6232-6236 (1982).
	Hsu et al., "Protease Activation Mutants of Sendai Virus: Sequence Analysis of the mRNA of the Fusion Protein (F) Gene and Direct Identification of the Cleavage-Activation Site," <i>Virology</i> 156(1):84-90 (1987).
	Huntley et al., "Phosphorylation of Sendai Virus Phosphoprotein by Cellular Protein Kinase C ζ ," <i>J. Biol. Chem.</i> 272(26):16578-16584 (1997).
	Ikeda et al., "Recombinant Sendai Virus-Mediated Gene Transfer into Adult Rat Retinal Tissue: Efficient Gene Transfer by Brief Exposure," <i>Exp. Eye Res.</i> 75(1):39-48 (2002).
	Imbert et al., "Highly Efficient Retroviral Gene Transfer into Human Primary T Lymphocytes Derived from Peripheral Blood," <i>Cancer Gene Ther.</i> 1(4):259-265 (1994).
	Inoue et al., "A New Sendai Virus Vector Deficient in the Matrix Gene Does Not Form Virus Particles and Shows Extensive Cell-to-Cell Spreading," <i>J. Virol.</i> 77(11):6419-6429 (2003).
	Inouye et al., "Potent Inhibition of Human Immunodeficiency Virus Type 1 in Primary T Cells and Alveolar Macrophages by a Combination Anti-Rev Strategy Delivered in an Adeno-Associated Virus Vector," <i>J. Virol.</i> 71(5):4071-4078 (1997).
	Jenkins et al., "Pulmonary Gene Therapy. Realistic Hope for the Future, or False Dawn in the Promised Land?" <i>Monaldi Arch. Chest Dis.</i> 59(1):17-24 (2003).
	Johnson et al., "Metalloproteinase Cleavable Linkers Can Target the Cytotoxicity of Fusogenic Membrane Glycoproteins in Gliomas," <i>Mol. Ther.</i> 3(5):S25(63) (2001).
	Karron et al., "Respiratory Syncytial Virus (RSV) SH and G Proteins are not Essential for Viral Replication <i>In Vitro</i> : Clinical Evaluation and Molecular Characterization of a Cold-Passaged, Attenuated RSV Subgroup B Mutant," <i>Proc. Natl. Acad. Sci. USA</i> 94(25):13961-13966 (1997).
	Kato et al., "Importance of the Cysteine-Rich Carboxy-Terminal Half of V Protein for Sendai Virus Pathogenesis," <i>J. Virol.</i> 71(10):7266-72 (1997).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AW/ (03/22/2009)

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Attorney Docket No. 50026/057001	
		Serial No.	10/562,408
		Applicant	You et al.
		371(c) Date	Dec. 7, 2006
		Group	1636
(37 C.F.R. § 1.98(b))		IDS Filed	January 2, 2008

	Kato et al., "Initiation of Sendai Virus Multiplication from Transfected cDNA or RNA with Negative or Positive Sense," <i>Genes Cells</i> 1(6):569-579 (1996).		
	Kato et al., "The Paramyxoviridae, Sendai Virus, V Protein Encodes a Luxury Function Required for Viral Pathogenesis," <i>EMBO J.</i> 16(3):578-587 (1997).		
	Kido et al., "The Human Mucus Protease Inhibitor and Its Mutants are Novel Defensive Compounds Against Infection with Influenza A and Sendai Viruses," <i>Biopolymers (Peptide Science)</i> 51(1):79-86 (1999).		
	Kondo et al., "Temperature-Sensitive Phenotype of a Mutant Sendai Virus Strain Is Caused by Its Insufficient Accumulation of the M Protein," <i>J. Biol. Chem.</i> 268(29):21924-21930 (1993).		
	Kridel et al., "Substrate Hydrolysis by Matrix Metalloproteinase-9," <i>J. Biol. Chem.</i> 276(23):20572-20578 (2001).		
	Kuwaybara et al., "tRNA ^{Val} -Heterodimeric Maxizymes with High Potential as Gene-Inactivating Agents: Simultaneous Cleavage at Two Sites in HIV-1 tat mRNA in Cultured Cells," <i>Proc. Natl. Acad. Sci. USA</i> 96(5):1886-1891 (1999).		
	Kühlcke et al., "Highly Efficient Retroviral Gene Transfer Based on Centrifugation-Mediated Vector Preloading of Tissue Culture Vessels," <i>Mol. Ther.</i> 5(4):473-478 (2002).		
	Lamb and Kolakofsky, "Paramyxoviridae: The Viruses and Their Replication," <i>Fields Virology</i> , 3 rd edition, Fields et al. (eds.), Lippincott Williams Wilkins: Philadelphia, Chapter 40, p. 1180-1181 (1996).		
	Lamb and Kolakofsky, "Paramyxoviridae: The Viruses and Their Replication," <i>Fundamental Virology</i> , 4 th edition, Knipe et al. (eds.), Lippincott Williams Wilkins: Philadelphia, Chapter 23, p. 689-691 (2001).		
	Leyrer et al., "Sendai Virus-Like Particles Devoid of Haemagglutinin-Neuraminidase Protein Infect Cells via the Human Asialoglycoprotein Receptor," <i>J. Gen. Virol.</i> 79(4):683-687 (1998).		
	Li et al., "A Cytoplasmic RNA Vector Derived from Nontransmissible Sendai Virus with Efficient Gene Transfer and Expression," <i>J. Virol.</i> 74(14):6564-6569 (2000).		
	Liang et al., "Expression of a Biologically Active Antiviral Antibody Using a Sindbis Virus Vector System," <i>Mol. Immunol.</i> 34(12-13):907-917 (1997).		
	Lin et al., "The RNA Binding Region of the Paramyxovirus SV V and P Proteins," <i>Virology</i> 238(2):460-469 (1997).		
	Manié et al., "Measles Virus Structural Components Are Enriched into Lipid Raft Microdomains: A Potential Cellular Location for Virus Assembly," <i>J. Virol.</i> 74(1):305-311 (2000).		
	Markwell et al., "An Alternative Route of Infection for Viruses: Entry by Means of the Asialoglycoprotein Receptor of a Sendai Virus Mutant Lacking Its Attachment Protein," <i>Proc. Natl. Acad. Sci. USA</i> 82(4):978-982 (1985).		
	Martin et al., "Retrovirus Targeting by Tropism Restriction to Melanoma Cells," <i>J. Virol.</i> 73(8):6923-6929 (1999).		

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U. S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Attorney Docket No. 50026/057001 Serial No. 10/562,408 Applicant You et al. 371(c) Date Dec. 7, 2006 Group 1636 IDS Filed January 2, 2008	
(37 C.F.R. § 1.98(b))			

	Masaki et al., "Angiogenic Gene Therapy for Experimental Critical Limb Ischemia: Acceleration of Limb Loss by Overexpression of Vascular Endothelial Growth Factor 165 but not of Fibroblast Growth Factor-2," <i>Circ. Res.</i> 90(9):966-973 (2002).
	Matsumura et al., "RNA Editing-Like Phenomenon in Paramyxovirus V Gene mRNA Observed in Insect Cells Infected with a Recombinant Baculovirus," <i>J. Gen. Virol.</i> 80(Pt. 1):117-123 (1999).
	McMoran et al., "G551D CF Mice Display an Abnormal Host Response and Have Impaired Clearance of <i>Pseudomonas</i> Lung Disease," <i>Am. J. Physiol. Lung Cell Mol. Physiol.</i> 281(3):L740-L747 (2001).
	Mebatsion et al., "Budding of Rabies Virus Particles in the Absence of the Spike Glycoprotein," <i>Cell</i> 84(6):941-951 (1996).
	Mebatsion et al., "Matrix Protein of Rabies Virus Is Responsible for the Assembly and Budding of Bullet-Shaped Particles and Interacts with the Transmembrane Spike Glycoprotein G," <i>J. Virol.</i> 73(1):242-250 (1999).
	Misaki et al., "Gene-Transferred Oligoclonal T Cells Predominantly Persist in Peripheral Blood from an Adenosine Deaminase-Deficient Patient during Gene Therapy," <i>Mol. Ther.</i> 3(1):24-27 (2001).
	Miura et al., "HVJ (Sendai Virus)-Induced Envelope Fusion and Cell Fusion Are Blocked by Monoclonal Anti-HN Protein Antibody That Does Not Inhibit Hemagglutination Activity of HVJ," <i>Exp. Cell Res.</i> 141(2):409-420 (1982).
	Morikawa et al., "Characterization of Temperature-Sensitive Mutants of Measles Virus," <i>Kitasato Arch. Exp. Med.</i> 64(1):15-30 (1991).
	Morimoto et al., "High Level Expression of a Human Rabies Virus-Neutralizing Monoclonal Antibody by a Rhabdovirus-Based Vector," <i>J. Immunol. Methods</i> 252(1-2):199-206 (2001).
	Mottet et al., "A Sendai Virus Vector Leading to the Efficient Expression of Mutant M Proteins Interfering with Virus Particle Budding," <i>Virology</i> 221(1):159-171 (1996).
	Mottet et al., "Characterization of Sendai Virus M Protein Mutants That Can Partially Interfere with Virus Particle Production," <i>J. Gen. Virol.</i> 80(11):2977-2986 (1999).
	Movassagh et al., "Retrovirus-Mediated Gene Transfer into T Cells: 95% Transduction Efficiency without Further In Vitro Selection," <i>Hum. Gene Ther.</i> 11(8):1189-1200 (2000).
	Nagai, "Paramyxovirus Replication and Pathogenesis. Reverse Genetics Transforms Understanding," <i>Rev. Med. Virol.</i> 9(2):83-99 (1999).
	Nieuwenhuizen et al., "Fluorogenic Peptide Amide Substrates for the Estimation of Plasminogen Activators and Plasmin," <i>Anal. Biochem.</i> 83(1):143-148 (1977).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AW/ (03/22/2009)

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No. Serial No. Applicant 371(c) Date Group IDS Filed	50026/057001 10/562,408 You et al. Dec. 7, 2006 1636 January 2, 2008
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(Use several sheets if necessary)</small>			
(37 C.F.R. § 1.98(b))			

	Oceandy et al., "Gene Complementation of Airway Epithelium in the Cystic Fibrosis Mouse is Necessary and Sufficient to Correct the Pathogen Clearance and Inflammatory Abnormalities," <i>Human Molecular Genetics</i> 11(9):1059-1067 (2002).
	Okano et al., "Recombinant Sendai Virus Vectors for Activated T Lymphocytes," <i>Gene Ther.</i> 10(16):1381-1391 (2003).
	Peng et al., "A Gene Delivery System Activatable by Disease-Associated Matrix Metalloproteinases," <i>Hum. Gene Ther.</i> 8(6):729-738 (1997).
	Peng et al., "Selective Transduction of Protease-Rich Tumors by Matrix-Metalloproteinase-Targeted Retroviral Vectors," <i>Gene Ther.</i> 6(9):1552-1557 (1999).
	Poliok et al., "High-Efficiency Gene Transfer into Normal and Adenosine Deaminase-Deficient T Lymphocytes Is Mediated by Transduction on Recombinant Fibronectin Fragments," <i>J. Virol.</i> 72(6):4882-4892 (1998).
	Ponimaskin et al., "Sendai Virosomes Revisited: Reconstitution with Exogenous Lipids Leads to Potent Vehicles for Gene Transfer," <i>Virology</i> 269(2):391-403 (2000).
	Puls and Minchin, "Gene Transfer and Expression of a Non-Viral Polyacation-Based Vector in CD4 ⁺ Cells," <i>Gene Ther.</i> 6(10):1774-1778 (1999).
	Ramani et al., "Novel Gene Delivery to Liver Cells Using Engineered Virosomes," <i>FEBS Lett.</i> 404(2-3):164-168 (1997).
	Rosenberg et al., "Gene Transfer into Humans—Immunotherapy of Patients with Advanced Melanoma, Using Tumor-Infiltrating Lymphocytes Modified by Retroviral Gene Transduction," <i>N. Engl. J. Med.</i> 323(9):570-578 (1990).
	Rudolf et al., "High-Efficiency Retroviral Vector Mediated Gene Transfer into Human Peripheral Blood CD4 ⁺ T Lymphocytes," <i>Gene Ther.</i> 3(8):695-705 (1996).
	Sasaki et al., "Development and Characterization of Cationic Liposomes Conjugated with HVJ (Sendai Virus): Reciprocal Effect of Cationic Lipid for In Vitro and In Vivo Gene Transfer," <i>Hum. Gene Ther.</i> 8(17):2133-2141 (1997).
	Sakai et al., "Accommodation of Foreign Genes into the Sendai Virus Genome: Sizes of Inserted Genes and Viral Replication," <i>FEBS Lett.</i> 456(2):221-226 (1999).
	Sanderson et al., "Sendai Virus Assembly: M Protein Binds to Viral Glycoproteins in Transit through the Secretory Pathway," <i>J. Virol.</i> 67(2):651-663 (1993).
	Sanderson et al., "Sendai Virus M Protein Binds Independently to Either the F or the HN Glycoprotein In Vivo," <i>J. Virol.</i> 68(1):69-76 (1994).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AW/ (03/22/2009)

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No. 50026/057001
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No. 10/562,408
(37 C.F.R. § 1.98(b))		Applicant You et al.
		371(c) Date Dec. 7, 2006
		Group 1636
		IDS Filed January 2, 2008

	Schwartz et al., "Synthetic DNA-Compacting Peptides Derived from Human Sequence Enhance Cationic Lipid-Mediated Gene Transfer In Vitro and In Vivo," <i>Gene Ther.</i> 6(2):282-292 (1999).
	Shiotani et al., "Skeletal Muscle Regeneration after Insulin-Like Growth Factor I Gene Transfer by Recombinant Sendai Virus Vector," <i>Gene Ther.</i> 8(14):1043-1050 (2001).
	Simons and Ikonen, "Functional Rafts in Cell Membranes," <i>Nature</i> 387(6633):569-572 (1997).
	Spiegel et al., "Pseudotype Formation of Moloney Murine Leukemia Virus with Sendai Virus Glycoprotein F," <i>J. Virol.</i> 72(6):5296-5302 (1998).
	Spiehler et al., "Chimeric Measles Viruses with a Foreign Envelope," <i>J. Virol.</i> 72(3):2150-2159 (1998).
	Stockschläder et al., "Expansion and Fibronectin-Enhanced Retroviral Transduction of Primary Human T Lymphocytes for Adoptive Immunotherapy," <i>J. Hematother. Stem Cell Res.</i> 8(4):401-410 (1999).
	Stonebraker et al., "Glycocalyx Restricts Adenoviral Access to Apical Receptors Expressed on Respiratory Epithelium In Vitro and In Vivo: Role for Tethered Mucins as Barriers to Luminal Infection," <i>J. Virol.</i> 78(24):13755-68 (2004).
	Stone-Huuslander et al., "Detection of an Interaction Between the HN and F Proteins in Newcastle Disease Virus-Infected Cells," <i>J. Virol.</i> 71(9):6287-6295 (1997).
	Stricker and Roux, "The Major Glycoprotein of Sendai Virus Is Dispensable for Efficient Virus Particle Budding," <i>J. Gen. Virol.</i> 72(7):1703-1707 (1991).
	Stricker et al., "The Sendai Virus Matrix Protein Appears to Be Recruited in the Cytoplasm by the Viral Nucleocapsid to Function in Viral Assembly and Budding," <i>J. Gen. Virol.</i> 75(5):1031-1042 (1994).
	Taira et al., "Transfection of Sendai Virus F Gene cDNA with Mutations at Its Cleavage Site and HN Gene cDNA into COS Cells Induces Cell Fusion," <i>Arch. Virol.</i> 140(1):187-194 (1995).
	Takimoto et al., "Role of Matrix and Fusion Proteins in Budding of Sendai Virus," <i>J. Virol.</i> 75(23):11384-11391 (2001).
	Tanabayashi et al., "Effect on Fusion Induction of Point Mutations Introduced into the F Protein of Mumps Virus," <i>Virology</i> 204(2):851-853 (1994).
	Tashiro et al., "Changes in Specific Cleavability of the Sendai Virus Fusion Protein: Implications for Pathogenicity in Mice," <i>J. Gen. Virol.</i> 73(6):1575-1579 (1992).
	Tashiro and Seto, "Determinants of Organ Tropism of Sendai Virus," <i>Front. Biosci.</i> 2:d588-d591 (1997).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Attorney Docket No.	50026/057001
		Serial No.	10/562,408
		Applicant	You et al.
		371(c) Date	Dec. 7, 2006
		Group	1636
(37 C.F.R. § 1.98(b))		IDS Filed	January 2, 2008

	Thomas et al., "G551D Cystic Fibrosis Mice Exhibit Abnormal Regulation of Inflammation in Lungs and Macrophages," <i>J. Immunol.</i> 164(7):3870-3877 (2000).
	Thompson and Portner, "Localization of Functional Sites on the Hemagglutinin-Neuraminidase Glycoprotein of Sendai Virus by Sequence Analysis of Antigenic and Temperature-Sensitive Mutants," <i>Virology</i> 160(1):1-8 (1987).
	Tokunaga et al., "Ribozyme-Mediated Inactivation of Mutant K-ras Oncogene in a Colon Cancer Cell Line," <i>Br. J. Cancer</i> 83(6):833-839 (2000).
	Tomasi et al., "Conjugation of Specific Antibodies to Sendai Virus Particles," <i>FEBS Lett.</i> 143(2):252-256 (1982).
	Tsuchida et al., "Adenovirus-Mediated Anti-K-ras Ribozyme Induces Apoptosis and Growth Suppression of Human Pancreatic Carcinoma," <i>Cancer Gene Ther.</i> 7(3):373-383 (2000).
	Tuffreau et al., "The Role of Haemagglutinin-Neuraminidase Glycoprotein Cell Surface Expression in the Survival of Sendai Virus-Infected BHK-21 Cells," <i>J. Gen. Viro.</i> 66(11):2313-2318 (1985).
	Tuohy et al., "T Cell Design for Therapy in Autoimmune Demyelinating Disease," <i>J. Neuroimmunol.</i> 107(2):226-232 (2000).
	Turk et al., "Determination of Protease Cleavage Site Motifs Using Mixture-Based Oriented Peptide Libraries," <i>Nat. Biotechnol.</i> 19(7):661-667 (2001).
	Uchida et al., "High Efficiency Gene Transfer into Murine T Cell Clones Using a Retroviral Vector," <i>J. Immunol.</i> 136(5):1876-1879 (1986).
	Verma et al., "Gene Therapy – Promises, Problems and Prospects," <i>Nature</i> 389(6648):239-242 (1997).
	Wickham et al., "Targeted Adenovirus-Mediated Gene Delivery to T Cells via CD3," <i>J. Virol.</i> 71(10):7663-7669 (1997).
	Yao et al., "Differences in the Role of the Cytoplasmic Domain of Human Parainfluenza Virus Fusion Proteins," <i>J. Virol.</i> 69(11):7045-7053 (1995).
	Yonemitsu et al., "HVJ (Sendai Virus)-Cationic Liposomes: A Novel and Potentially Effective Liposome-Mediated Technique for Gene Transfer to the Airway Epithelium," <i>Gene Ther.</i> 4(7):631-638 (1997).
	Yonemitsu et al., "Efficient Gene Transfer to Airway Epithelium Using Recombinant Sendai Virus," <i>Nat. Biotechnol.</i> 18(9):970-973 (2000).
	Yoshida et al., "Membrane (M) Protein of HVJ (Sendai Virus): Its Role in Virus Assembly," <i>Virology</i> 71(1):143-161 (1976).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50026/057001
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/562,408
		Applicant	You et al.
		371(c) Date	Dec. 7, 2006
		Group	1636
(37 C.F.R. § 1.98(b))		IDS Filed	January 2, 2008

	Yu et al., "CD28-Specific Antibody Prevents Graft-Versus-Host Disease in Mice," <i>J. Immunol.</i> 164(9):4564-4568 (2000).
	Zhang et al., "Anti-Tumorigenic Effect of a K-ras Ribozyme Against Human Lung Cancer Cell Line Heterotransplants in Nude Mice," <i>Gene Ther.</i> 7(23):2041-2050 (2000).
	Zhirmov, "Solubilization of Matrix Protein M1/M from Virions Occurs at Different pH for Orthomyxo- and Paramyxoviruses," <i>Virology</i> 176(1):274-279 (1990).
	English Translation of International Preliminary Examination Report for PCT/JP2004/009617

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AW/ (03/22/2009)

EXAMINER /Anne Marie Wehbe/ (03/22/2009)	DATE CONSIDERED 03/22/2009
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	